中文摘要：

目的 探讨ercc1、rrm1基因在侵袭性非霍奇金淋巴瘤中的表达及其与患者临床特征和预后的关系。方法 采用Taqman RT-PCR法检测65例侵袭性非霍奇金淋巴瘤患者肿瘤组织中ercc1和rrm1基因的表达情况，分析其与患者临床特征及无进展生存、总生存的关系。结果 （1）ercc1基因高表达仅出现于侵袭性T细胞淋巴瘤患者，发生率18%，主要表达在T淋巴母细胞性和外周T细胞性； rrm1基因在侵袭性B和T细胞淋巴瘤中均有高表达，B细胞性表达率较T细胞性淋巴瘤高（8/31 vs.2/33，P=0.044）。（2）ercc1、rrm1基因高表达在侵袭性B和T细胞淋巴瘤中均与患者较短的无进展生存期（χ^24.323，P=0.038）和总生存期（χ^25.728，P=0.017）有关。 结论 （1）侵袭性淋巴瘤对铂类与吉西他滨药物敏感。（2）ercc1、rrm1基因的表达对侵袭性非霍奇金淋巴瘤预 后的预测均有意义。

英文摘要：

Objective To investigate the relations between the expression of the ercc1 and rrm1 genes in invasive non-hodgkin＇s lymphoma and the clinical features and prognosis. Methods The Taqman RT - PCR method was used to detect the expressions of rrm1 and ercc1 genes existed in the invasive non-hodgkin＇s lymphoma from 65 cases patients＇ tumor tissues. Then the χ^2 test, Fisher ＇s precise inspection, Kaplan-Meier survival analysis methods were performed to analyze the relationships between the clinical features of patients,PFS and OS.Results （1）The high expression of ercc1 gene was only appeared in the invasive non-hodgkin＇s lymphoma patients, the incidence was 18%, mainly expressed in T lymphoblastoid cells and peripheralT cells; the high xpression of rrm1 gene was appeared both in the aggressive B-and T-cell lymphoma ,and much higher in the B cells （8/31 vs.2/33,P=0.044）.（2）The high expression of ercc 1 gene and rrm 1 gene in the invasive non-hodgkin＇s lymphoma patients were concerned with shorter progression-free survival （χ^24.323,P=0.038） and overall survival time （χ^25.728,P=0.017）.Conclusion （1）This study prompts that the aggressive lymphoma is sensitive to platinum and gemcitabine. （2）The expressions of ercc1 and rrm1 are significant to the aggressive non-Hodgkin＇s lymphoma＇s prognosis and forecast.